ADA Advises Wider Use of Diabetes Medications

For its 2020 recommendations, the American Diabetes Association (ADA) is now advising doctors to consider prescribing sodium glucose co-transporter 2 (SGLT2) inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists to patients at high risk for heart failure or chronic kidney disease (CKD), not only in patients who already have the disease. Read more

Posted in Drugs